基于粘膜保护机制探讨胃痞消对CAG大鼠干预研究
|
摘要
慢性萎缩性胃炎(Chronic atrophic gastritic, CAG)是消化系统的常见病,病情演变长期,不易治愈,最严重的是引致胃癌前或胃癌病变。随着医学技术的发展,近年来引起国内外医学界的广泛重视,并从多角度对本病的诊治进行研究。CAG是以胃粘膜局部性或广泛性的固有腺体萎缩,数量减少,粘膜层变薄,粘膜肌层变厚为主要病理改变的一种慢性胃炎。慢性萎缩性胃炎分属于中医学中“胃脘痛”、“痞满”、“呃逆”、“嗳气”、“嘈杂”、“吞酸”、“呕吐”等范畴,多由于脾胃功能失调所致,病机主要是脾胃虚弱、气血阻滞和湿热内蕴。本研究建立了慢性萎缩性胃炎大鼠模型,依据辨证论治和导师的临床经验研制了胃痞消方(太子参、黄芪、白术、丹参、白花蛇舌草等)为干预药物。本方具有健脾益气、活血化瘀、清热解毒的作用,在临床上取得了较好的疗效。
目的：
从CAG大鼠胃粘膜结构、胃酸含量、微血管密度(MVD)探讨胃痞消方对大鼠慢性萎缩性胃炎胃粘膜保护作用通过指标：胃液胃酸、微血管分面密度(MVD)、血清SOD、 MDA含量的变化,探讨胃痞消治疗慢性萎缩性胃炎的作用机制,为其临床应用提供科学的实验依据。
方法：
选用体重200±20g SD大鼠共80只,分为空白组及模型组,空白组10只,模型组70只。空白组常规喂养,模型组采用以化学损伤为主的综合法复制慢性萎缩性胃炎大鼠模型。8周末时处死10只大鼠,通过光镜下观察确认造模成功,后将60只造模大鼠随机分为模型对照组、胃痞消高剂量组,中剂量组、低剂量组、维酶素组,每组12只。连续给药两个月,第16周末处死全部大鼠。取胃液测定胃酸、观察胃粘膜病理结构、使用免疫组化法(Envision法)检测胃粘膜微血管密度、测定大鼠血清SOD及MDA含量。
结果：
1、胃粘膜结构变化CAG大鼠模型组胃粘膜固有腺体结构消失、胃粘膜变薄、粘膜肌层变厚,可见弥漫慢性炎细胞浸润,甚至有淋巴滤泡形成。并且细胞具有一定程度异型性,细胞形态多样,细胞核的形态也不规则,呈中到重度不典型增生。
胃痞消方三个剂量组胃粘膜结构变化显著增厚,固有腺体显著增多,部分区域腺体排列紊乱、可见慢性炎细胞浸润。具体模型对照组100%有慢性炎症表现,均有轻、中、重度的程度以重度为主。模型组与正常组比较差别有统计意义(P＜0.01)。维酶素组治疗后50%大鼠胃粘膜表现慢性炎症减退,与模型组相比有差异；胃痞消三个组治疗后慢性炎症只有25%到33.33%,与模型组比较差别有统计意义(P＜0.01)。
模型对照组有11只大鼠表现固有腺体萎缩从轻度至重度占91.67%,与空白对照组比较(0%)差别有统计意义(P＜0.01)。维酶素组还有7只大鼠固有腺体萎缩占58.33%,治疗有效果但与模型对照组比较差别无统计意义(P＞0.05)。胃痞消高、中、低剂量三个组固有腺体萎缩均有再生现象,腺体萎缩表现依次是33.33%、41.67%、41.67%,与模型组相比差别有统计意义(P＜0.05)。
模型对照组有75%肠上皮化生或异型增生。除了胃痞消高剂量组以外,胃痞消中、低剂量和维酶素组,肠上皮化生与异型增生有逆转现象但不明显,与模型组比较差别无统计意义。各个组均未见癌变。
模型对照组大鼠胃壁厚度显著变薄平均347.0±45.50μm,与空白对照组(655.3±42.06μm)比较差别有统计意义。维酶素组和胃痞消三个组胃壁厚度明显增厚(从448.8±47.40μm至539.8±69.40μm)与模型组比较差别均有统计意义(P＜0.05),虽然维酶素组和胃痞消各剂量组胃壁均显示增厚特别是胃痞消高剂量组但与空白对照组相比还没达到正常,统计有差异(P＜0.05)。
2、胃液胃酸变化
模型对照组大鼠pH值3.02±1.13增高(空白对照组1.45±0.67)、总胃酸度112.54±7.54mmol/L减低(空白组225.60±18.74mmol/L),表明慢性萎缩性胃炎胃粘膜腺体分泌胃酸减少。胃痞消三个剂量组和维酶素组与模型对照组比较pH值明显减低从1.37±0.53至1.84±0.95、总胃酸度升高202.25±7.09mmol/L到230.65±11.29mmol/L,差异具有统计学意义(P＜0.05),表明胃痞消方和维酶素都有恢复胃粘膜细胞胃酸分泌的功能。
3、胃粘膜微血管密度变化
模型对照组CAG大鼠胃粘膜微血管密度减少(10.25±4.58)与空白对照组比较(30.90±9.00)差别有统计意义(P＜0.05)。过胃痞消、维酶素治疗后胃粘膜微血管密度增多恢复接近正常(从19.25±5.99至25.25±9.42),统计显示胃痞消高剂量组与空白对照组相比无差异(P＞0.05)。
4、血清SOD.MDA含量变化
模型对照组CAG大鼠血清SOD的活力明显下降(与空白对照组相比P＜0.05),MDA数值明显增高(P＜0.05),维酶素组和胃痞消三个剂量组与模型对照组比较,SOD活力明显升高(P＜0.05),MDA数值明显降低(P＜0.05)。胃痞消高剂量组与维酶素组比较SOD活力升高、MDA降低差异均有统计意义,胃痞消中低剂量与维酶素组比较差异无有统计意义。结果表明胃痞消方通过提高超氧化物歧化酶活力清除自由基,并显著降低丙二醛含量。
结论：
①对慢性萎缩性胃炎大鼠,胃痞消方能明显改善其胃粘膜炎症并能使已发生萎缩的腺体恢复再生、使胃粘膜增厚。该方有所改善肠上皮化生或异型增生现象,但效果并不明显。
②通过pH值降低,胃液酸度增高表明胃痞消方有恢复胃粘膜壁细胞增殖的作用,使慢性萎缩性胃炎胃上皮细胞增殖／凋亡平衡得到有效调节。
③胃痞消方的活血化瘀的作用使慢性萎缩性胃炎大鼠胃粘膜微血管密度恢复接近正常,对胃粘膜萎缩增加供应血液从而促进胃粘膜损伤恢复。此为胃痞消方治疗慢性萎缩性胃炎的一个重要机制。
④胃痞消方通过升高CAG大鼠血清SOD活性、降低MDA含量表明该方有保护胃粘膜、防御损伤细胞的作用。
胃痞消方对CAG模型大鼠胃粘膜萎缩能起到改善和恢复作用。其作用机制可能与其增加胃粘膜微血管密度、恢复胃粘膜细胞结构、增强胃粘膜屏障功能、调节胃酸分泌、抗自由基损伤等有关。
Object ive
Chronic atrophic gastritis (CAG) is the common disease in the digestive system, the disease often is persistent and difficult for cure. The most serious consequences it may cause is precancerous stomach cancer or stomach cancer. As the development of medicine, more and more attention are being paid by the medical specialist circle in carrying out various research perspectives on diagnosis and treatment.
CAG is a type of chronic gastritis, with the major pathological sign is that the gastric excretory gland is atrophied, with loss of gastric glandular cells and corrosive gastric atrophic mucosa, the muscular layer is thickened. Chronic gastric mucosal atrophy is viewed by the traditional medicine with symptoms known as:"Epigastric pain/Stomachache","Epigastric Fullness""hiccough","Belch","Vomit "... The main cause is due to disorders the functions of the spleen and stomach, pathogenic mechanism is mainly due to weakened spleen-stomach, Blood depression&Qi stagnation, moist heat Within the depression. Based on dialectical methodology combined with clinical experience, the remedy Weipixiao was researched and developed which has the effect of strengthening the stomach and blood, clearing the blood stagnation, clear the heat, detoxification (including the medical herbs Taizishen (Radix Pseudostellariae Heterophyllae), Huangqi (Astragalus membranaceus); Baizhu (Atractylodes macrocephala)Danshen (Salvia miltiorrhiza) Baihuasheshecao (Hedyotis diffusa).... In this design, we caused the model of rat with Chronic gastric mucosal atrophy and administered with Weipixiao for treatment to study on the mechanism of recovering effect and gastric mucosa protection.
Purpose:To study the mechanisms of gastric mucosal protection through a number of criteria:the gastric acidity, the change of the micro blood-vessel of the gastric mucosa, levels of SOD, MDA serum and evaluation recovery of gastric lining of the rat with gastric atrophy through the ultramicroscopic structure image. Via this, the initial evaluation on mechanism of the effect of Weipixiao will be made to serve as a scientific basis for the treatment of gastric mucosal atrophy in clinically.
Methods
Selected80Wistar rats, weighing200±20g.10of them was used as the control group,70was put in a model for causing them diseased. The control group was fed in normal condition, the diseased model were mainly injured by the method of using chemical. After8weeks of causing disease, killed10of them to make dyed stomach specimens to ascertain the successful creation of a diseased pattern, then the rest of60rates was divided into5groups x12rats:comparison pattern, vitacoenzym, high-dose weipixiao, medium-dose weipixiao and low-dose weipixiao. Giving the rats continuous medication for8weeks, at the end of the16th week, killed all rats, measured the amount of gastric acidity, observed the mucosal structural changes, gastric ultramicroscopic blood image of gastric mucosa, quantified the SOD activity, content of MDA serum.
Results
Rats were successfully caused with CAG:disease-caused rat model had excretory glands shrunken, reducing in the quantity; gastric mucosa was thinly atrophied, muscular layer of mucosa was thickened. It is possible to observe that the inflammatory dense cell infiltration, even including formed cluster of lymphocytes. Moreover, it is possible to see heteromorphy, pyknomorphous thymocyte, the karyoplast also changed not according to the rule, atypical proliferative image from moderate to severe degree.
The groups of rats given with high, medium and low doses of Weipixiao all show change with thickened gastric mucosa, with more proliferative glands, with numerous new images with small size. It is seen in some areas the image of glands in chaotic order, and images of chronic inflammatory infiltration cell. Namely,100%in diseased rat group had sign of chronic infection with manifestations ranging from mild, moderate to severe. The majority is severe cases, compared with control group, the difference of statistical significance with P<0.01. In vitacoenzyme-used rat group50%of the rats still had chronic inflammation compared with diseased rat with differences. For3groups of rats which was given weipixiao, only had inflammatory images was note with25%to33.33%compared with the diseased rat group, the difference is statistically significant with P<0.01.
In the diseased rat model groups,11rats had signs of mucosal atrophy from mild to severe degree, accounting for91.67%, compared with the control group. The difference is statistically significant with P<0.01. In the vitacoenzyme Group, still7rats with signs of mucosal atrophy was noted, accounting for58.33%, the rate is reduced compared with the diseased model group but the difference is not statistically significant. The3groups are obsersed to have glandular regeneration, only remain with atropic image33.33%to41.67%, compared with the model group, showing difference with P<0.05.
The diseased group75%show intestinal tract or atypical hyperplasia, the group administered with vitacoenzyme and weipixiao have lower rates, but the difference was of no statistical significance. The groups had no cancer imaging.
The diseased group has gastric mucosa thickness showing clearly the average atrophy347.0±45.50μm compared with the control group655.3±42.06μm, the difference is of statistical significance. The Vitacoenzyme group and3groups using Weipixiao have mucosal thickness changed from448.8±47.40μm to539.8±69.40μm, compared with the diseased group difference was noted, but compared with the control group no difference was noted.
The pH value of gastric juice of the diseased rat model considerably increased3.02±1.13(compared with control group was1.45±0.67), total acidity decreased112.54±7.54mmol/L (compared with the control group225.60±18.74mmol/L) expressed in glands of the atrophic gastric mucosa and reduced gastric secretion. A clear reduction of pH value of the weipixiao group compared with the diseased group was noted from1.37±0.53to1.84±0.95, the total acidity increased from202.25±7.09mmol/L to230.65±11.29mmol/L, the difference is statistically significant. This result proves that the remedy has the effect of recovering gastric mucosal cells functioning the gastric acid secretion.
The density of microscopic blood vessel of gastric mucosa in model group was significantly reduced (10.25±4.58) compared with the control group (30.90±9.00) the difference is statistically significant with P<0.05. The Weipixiao, vitacoenzyme groups have sign of increased number of microscopic blood vessels close to the control group (from19.25±5.99to25.25±9.42), the statistics show that there is no difference between Weipixiao high-dosed group compared with the control group.
Serum SOD activity in CAG rat of disease-caused model group was significantly reduced, the MDA levels was highly elevated, compared with control group P<0.05. The SOD activity increased significantly (P<0.05) of the vitacoenzyme and3Weipixiao groups was noted with significantly increased (P<0.05), MDA level was remarkably decreased (P<0.05). The result has proven that the Weipixiao has effect of eliminating oxidization substances via the SOD enzyme, demonstrated in the reduction of MDA level.
Conelusion
1. The Weipixiao remedy has effect of improving the gastric mucosa inflamation in CAG rats, restoring and regeneration of the atrophic glands. This means that mucosal thickness is increased, partly improving the phenomenon of atypical proliferative and appearance of intestinal gland.
2. With the effect of reducing the pH value, increasing gastric acidity, this demonstrates that Weipixiao has effect of restoring the gastric mucosa cell, regulating the balance of reproduction and destruction by gastric epithelium cells.
3. The clearing effect to the blood stasis of Weipixiao in restoring the density of micro blood vessels which is reduced because of chronic inflammatory atrophy by promoting to blood supply of the atrophic mucosa.
4. The remedy has protective effect to the gastric mucosa, preventing cell damage by increasing the activity of SOD, reduction of MDA serum content.
The remedy "Weipixiao" has good effect for treatment of rats with chronic gastric mucosal atrophy in experiment, helping the recovery of atrophic mucosa. The mechanism may be associated with the restoration of density of micro blood vessels, recovery of mucosal cells, strengthening the system to prevent cell damage, antioxidant, controlling the gastric acidity secretion.
目的：
从CAG大鼠胃粘膜结构、胃酸含量、微血管密度(MVD)探讨胃痞消方对大鼠慢性萎缩性胃炎胃粘膜保护作用通过指标：胃液胃酸、微血管分面密度(MVD)、血清SOD、 MDA含量的变化,探讨胃痞消治疗慢性萎缩性胃炎的作用机制,为其临床应用提供科学的实验依据。
方法：
选用体重200±20g SD大鼠共80只,分为空白组及模型组,空白组10只,模型组70只。空白组常规喂养,模型组采用以化学损伤为主的综合法复制慢性萎缩性胃炎大鼠模型。8周末时处死10只大鼠,通过光镜下观察确认造模成功,后将60只造模大鼠随机分为模型对照组、胃痞消高剂量组,中剂量组、低剂量组、维酶素组,每组12只。连续给药两个月,第16周末处死全部大鼠。取胃液测定胃酸、观察胃粘膜病理结构、使用免疫组化法(Envision法)检测胃粘膜微血管密度、测定大鼠血清SOD及MDA含量。
结果：
1、胃粘膜结构变化CAG大鼠模型组胃粘膜固有腺体结构消失、胃粘膜变薄、粘膜肌层变厚,可见弥漫慢性炎细胞浸润,甚至有淋巴滤泡形成。并且细胞具有一定程度异型性,细胞形态多样,细胞核的形态也不规则,呈中到重度不典型增生。
胃痞消方三个剂量组胃粘膜结构变化显著增厚,固有腺体显著增多,部分区域腺体排列紊乱、可见慢性炎细胞浸润。具体模型对照组100%有慢性炎症表现,均有轻、中、重度的程度以重度为主。模型组与正常组比较差别有统计意义(P＜0.01)。维酶素组治疗后50%大鼠胃粘膜表现慢性炎症减退,与模型组相比有差异；胃痞消三个组治疗后慢性炎症只有25%到33.33%,与模型组比较差别有统计意义(P＜0.01)。
模型对照组有11只大鼠表现固有腺体萎缩从轻度至重度占91.67%,与空白对照组比较(0%)差别有统计意义(P＜0.01)。维酶素组还有7只大鼠固有腺体萎缩占58.33%,治疗有效果但与模型对照组比较差别无统计意义(P＞0.05)。胃痞消高、中、低剂量三个组固有腺体萎缩均有再生现象,腺体萎缩表现依次是33.33%、41.67%、41.67%,与模型组相比差别有统计意义(P＜0.05)。
模型对照组有75%肠上皮化生或异型增生。除了胃痞消高剂量组以外,胃痞消中、低剂量和维酶素组,肠上皮化生与异型增生有逆转现象但不明显,与模型组比较差别无统计意义。各个组均未见癌变。
模型对照组大鼠胃壁厚度显著变薄平均347.0±45.50μm,与空白对照组(655.3±42.06μm)比较差别有统计意义。维酶素组和胃痞消三个组胃壁厚度明显增厚(从448.8±47.40μm至539.8±69.40μm)与模型组比较差别均有统计意义(P＜0.05),虽然维酶素组和胃痞消各剂量组胃壁均显示增厚特别是胃痞消高剂量组但与空白对照组相比还没达到正常,统计有差异(P＜0.05)。
2、胃液胃酸变化
模型对照组大鼠pH值3.02±1.13增高(空白对照组1.45±0.67)、总胃酸度112.54±7.54mmol/L减低(空白组225.60±18.74mmol/L),表明慢性萎缩性胃炎胃粘膜腺体分泌胃酸减少。胃痞消三个剂量组和维酶素组与模型对照组比较pH值明显减低从1.37±0.53至1.84±0.95、总胃酸度升高202.25±7.09mmol/L到230.65±11.29mmol/L,差异具有统计学意义(P＜0.05),表明胃痞消方和维酶素都有恢复胃粘膜细胞胃酸分泌的功能。
3、胃粘膜微血管密度变化
模型对照组CAG大鼠胃粘膜微血管密度减少(10.25±4.58)与空白对照组比较(30.90±9.00)差别有统计意义(P＜0.05)。过胃痞消、维酶素治疗后胃粘膜微血管密度增多恢复接近正常(从19.25±5.99至25.25±9.42),统计显示胃痞消高剂量组与空白对照组相比无差异(P＞0.05)。
4、血清SOD.MDA含量变化
模型对照组CAG大鼠血清SOD的活力明显下降(与空白对照组相比P＜0.05),MDA数值明显增高(P＜0.05),维酶素组和胃痞消三个剂量组与模型对照组比较,SOD活力明显升高(P＜0.05),MDA数值明显降低(P＜0.05)。胃痞消高剂量组与维酶素组比较SOD活力升高、MDA降低差异均有统计意义,胃痞消中低剂量与维酶素组比较差异无有统计意义。结果表明胃痞消方通过提高超氧化物歧化酶活力清除自由基,并显著降低丙二醛含量。
结论：
①对慢性萎缩性胃炎大鼠,胃痞消方能明显改善其胃粘膜炎症并能使已发生萎缩的腺体恢复再生、使胃粘膜增厚。该方有所改善肠上皮化生或异型增生现象,但效果并不明显。
②通过pH值降低,胃液酸度增高表明胃痞消方有恢复胃粘膜壁细胞增殖的作用,使慢性萎缩性胃炎胃上皮细胞增殖／凋亡平衡得到有效调节。
③胃痞消方的活血化瘀的作用使慢性萎缩性胃炎大鼠胃粘膜微血管密度恢复接近正常,对胃粘膜萎缩增加供应血液从而促进胃粘膜损伤恢复。此为胃痞消方治疗慢性萎缩性胃炎的一个重要机制。
④胃痞消方通过升高CAG大鼠血清SOD活性、降低MDA含量表明该方有保护胃粘膜、防御损伤细胞的作用。
胃痞消方对CAG模型大鼠胃粘膜萎缩能起到改善和恢复作用。其作用机制可能与其增加胃粘膜微血管密度、恢复胃粘膜细胞结构、增强胃粘膜屏障功能、调节胃酸分泌、抗自由基损伤等有关。
Object ive
Chronic atrophic gastritis (CAG) is the common disease in the digestive system, the disease often is persistent and difficult for cure. The most serious consequences it may cause is precancerous stomach cancer or stomach cancer. As the development of medicine, more and more attention are being paid by the medical specialist circle in carrying out various research perspectives on diagnosis and treatment.
CAG is a type of chronic gastritis, with the major pathological sign is that the gastric excretory gland is atrophied, with loss of gastric glandular cells and corrosive gastric atrophic mucosa, the muscular layer is thickened. Chronic gastric mucosal atrophy is viewed by the traditional medicine with symptoms known as:"Epigastric pain/Stomachache","Epigastric Fullness""hiccough","Belch","Vomit "... The main cause is due to disorders the functions of the spleen and stomach, pathogenic mechanism is mainly due to weakened spleen-stomach, Blood depression&Qi stagnation, moist heat Within the depression. Based on dialectical methodology combined with clinical experience, the remedy Weipixiao was researched and developed which has the effect of strengthening the stomach and blood, clearing the blood stagnation, clear the heat, detoxification (including the medical herbs Taizishen (Radix Pseudostellariae Heterophyllae), Huangqi (Astragalus membranaceus); Baizhu (Atractylodes macrocephala)Danshen (Salvia miltiorrhiza) Baihuasheshecao (Hedyotis diffusa).... In this design, we caused the model of rat with Chronic gastric mucosal atrophy and administered with Weipixiao for treatment to study on the mechanism of recovering effect and gastric mucosa protection.
Purpose:To study the mechanisms of gastric mucosal protection through a number of criteria:the gastric acidity, the change of the micro blood-vessel of the gastric mucosa, levels of SOD, MDA serum and evaluation recovery of gastric lining of the rat with gastric atrophy through the ultramicroscopic structure image. Via this, the initial evaluation on mechanism of the effect of Weipixiao will be made to serve as a scientific basis for the treatment of gastric mucosal atrophy in clinically.
Methods
Selected80Wistar rats, weighing200±20g.10of them was used as the control group,70was put in a model for causing them diseased. The control group was fed in normal condition, the diseased model were mainly injured by the method of using chemical. After8weeks of causing disease, killed10of them to make dyed stomach specimens to ascertain the successful creation of a diseased pattern, then the rest of60rates was divided into5groups x12rats:comparison pattern, vitacoenzym, high-dose weipixiao, medium-dose weipixiao and low-dose weipixiao. Giving the rats continuous medication for8weeks, at the end of the16th week, killed all rats, measured the amount of gastric acidity, observed the mucosal structural changes, gastric ultramicroscopic blood image of gastric mucosa, quantified the SOD activity, content of MDA serum.
Results
Rats were successfully caused with CAG:disease-caused rat model had excretory glands shrunken, reducing in the quantity; gastric mucosa was thinly atrophied, muscular layer of mucosa was thickened. It is possible to observe that the inflammatory dense cell infiltration, even including formed cluster of lymphocytes. Moreover, it is possible to see heteromorphy, pyknomorphous thymocyte, the karyoplast also changed not according to the rule, atypical proliferative image from moderate to severe degree.
The groups of rats given with high, medium and low doses of Weipixiao all show change with thickened gastric mucosa, with more proliferative glands, with numerous new images with small size. It is seen in some areas the image of glands in chaotic order, and images of chronic inflammatory infiltration cell. Namely,100%in diseased rat group had sign of chronic infection with manifestations ranging from mild, moderate to severe. The majority is severe cases, compared with control group, the difference of statistical significance with P<0.01. In vitacoenzyme-used rat group50%of the rats still had chronic inflammation compared with diseased rat with differences. For3groups of rats which was given weipixiao, only had inflammatory images was note with25%to33.33%compared with the diseased rat group, the difference is statistically significant with P<0.01.
In the diseased rat model groups,11rats had signs of mucosal atrophy from mild to severe degree, accounting for91.67%, compared with the control group. The difference is statistically significant with P<0.01. In the vitacoenzyme Group, still7rats with signs of mucosal atrophy was noted, accounting for58.33%, the rate is reduced compared with the diseased model group but the difference is not statistically significant. The3groups are obsersed to have glandular regeneration, only remain with atropic image33.33%to41.67%, compared with the model group, showing difference with P<0.05.
The diseased group75%show intestinal tract or atypical hyperplasia, the group administered with vitacoenzyme and weipixiao have lower rates, but the difference was of no statistical significance. The groups had no cancer imaging.
The diseased group has gastric mucosa thickness showing clearly the average atrophy347.0±45.50μm compared with the control group655.3±42.06μm, the difference is of statistical significance. The Vitacoenzyme group and3groups using Weipixiao have mucosal thickness changed from448.8±47.40μm to539.8±69.40μm, compared with the diseased group difference was noted, but compared with the control group no difference was noted.
The pH value of gastric juice of the diseased rat model considerably increased3.02±1.13(compared with control group was1.45±0.67), total acidity decreased112.54±7.54mmol/L (compared with the control group225.60±18.74mmol/L) expressed in glands of the atrophic gastric mucosa and reduced gastric secretion. A clear reduction of pH value of the weipixiao group compared with the diseased group was noted from1.37±0.53to1.84±0.95, the total acidity increased from202.25±7.09mmol/L to230.65±11.29mmol/L, the difference is statistically significant. This result proves that the remedy has the effect of recovering gastric mucosal cells functioning the gastric acid secretion.
The density of microscopic blood vessel of gastric mucosa in model group was significantly reduced (10.25±4.58) compared with the control group (30.90±9.00) the difference is statistically significant with P<0.05. The Weipixiao, vitacoenzyme groups have sign of increased number of microscopic blood vessels close to the control group (from19.25±5.99to25.25±9.42), the statistics show that there is no difference between Weipixiao high-dosed group compared with the control group.
Serum SOD activity in CAG rat of disease-caused model group was significantly reduced, the MDA levels was highly elevated, compared with control group P<0.05. The SOD activity increased significantly (P<0.05) of the vitacoenzyme and3Weipixiao groups was noted with significantly increased (P<0.05), MDA level was remarkably decreased (P<0.05). The result has proven that the Weipixiao has effect of eliminating oxidization substances via the SOD enzyme, demonstrated in the reduction of MDA level.
Conelusion
1. The Weipixiao remedy has effect of improving the gastric mucosa inflamation in CAG rats, restoring and regeneration of the atrophic glands. This means that mucosal thickness is increased, partly improving the phenomenon of atypical proliferative and appearance of intestinal gland.
2. With the effect of reducing the pH value, increasing gastric acidity, this demonstrates that Weipixiao has effect of restoring the gastric mucosa cell, regulating the balance of reproduction and destruction by gastric epithelium cells.
3. The clearing effect to the blood stasis of Weipixiao in restoring the density of micro blood vessels which is reduced because of chronic inflammatory atrophy by promoting to blood supply of the atrophic mucosa.
4. The remedy has protective effect to the gastric mucosa, preventing cell damage by increasing the activity of SOD, reduction of MDA serum content.
The remedy "Weipixiao" has good effect for treatment of rats with chronic gastric mucosal atrophy in experiment, helping the recovery of atrophic mucosa. The mechanism may be associated with the restoration of density of micro blood vessels, recovery of mucosal cells, strengthening the system to prevent cell damage, antioxidant, controlling the gastric acidity secretion.
引文
[1]罗云坚,余绍源,黄穗平.消化科专病中医临床诊治.人民卫生出版社,2004：75-116.
[2]Melanie Nicole Weck and Hermann Brenner. Prevalence of chronic atrophic gastritis in different parts of the world. Cancer Epidemiol Biomarkers,2006, Prev 15 (6):1083-94.
[3]戴德哉.临床医学概论.科学出版社,2011：124-126.
[4]柴可夫.慢性胃炎.科学技术文献出版社,2000：1-4.
[5]孟静岩.慢性萎缩性胃炎.中国医药科技出版社,2003：28-33.
[6]张经济,连至诚,许冠荪,等.消化道生理及病理生理学.广东科技出版社,1997：448-479.
[7]陆为民,刘万里,吴静,徐陆周,等.慢性萎缩性胃炎中医特色疗法.人民军医出版社,2012.
[8]刘友章.中西医结合内科学.广东高等教育出版社,2007：333-339.
[9]陆为民,万力生.中医内科临证治要.学苑出版社,2012：120-132.
[10]朱文锋,何清湖.现代中医临床诊断学.人民卫生出版社,2003：403-411,549-550.
[11]张杰,章天寿.从“虚”“毒”“瘀”论治慢性萎缩性胃炎.中国中医基础医学杂志,2005,11(1)：44-45.
[12]张道友.现代临床检验正常值手册.安徽科学技术出版社,2001：101-108.
[13]孙自镛.实验诊断临床指南.第二版.科学出版社,2004：187-191.
[14]魏玉霞.慢性萎缩性胃炎近10年中医文献研究.博士学位论文.北京中医药大学,2012.
[15]Stater IF. Freeracdicalsand tissue injury:Fact and ficttion Brj Cancer.1987, ss (Sujpp. Ⅷ):5.
[16]金武丕.慢性萎缩性胃炎病人胃粘膜MDA和SOD测定及其意义.中国基层医药,1999,(6)5：271-272.
[17]魏玥.益气化瘀解毒法对慢性萎缩性胃炎伴异型增生大鼠干预的实验研究.博士学位论文.北京中医药大学,2012.
[18]孙晓明,孟凡明,李丽晴,等.健脾活血.方治疗慢性萎缩性胃炎伴肠化增生55例.陕西中医,2011,32(1)：11-12.
[19]张风岭. 自拟扶正活血汤治疗慢性萎缩性胃炎58例观察.中医药临床杂志,2005,17(5)：479-480.
[20]赖逸贵.胃炎Ⅰ号对大鼠慢性萎缩性胃炎胃粘膜细胞外基质成份调控机制研究.博士学位论文.广州中医药大学,2009.
[21]苏和.牛兴东学术思想及治疗慢性萎缩性胃炎经验总结.硕士学位论文.北京中医药大 学,2012.
[22]张秀娟.中药通过线粒体途径治疗胃癌前病变大鼠的实验研究.博士学位论文.辽宁中医药大学,2010.
[23]许颖,陈菲.益胃煎加减治疗慢性萎缩性胃炎气虚血瘀型30例.陕西中医,2010,(31)9：1130-1131.
[24]马然.慢性萎缩性胃炎中医症候学研究.中医学专业七年制学位论文.北京中医药大学,2005.
[25]延卫东.萎胃复元汤治疗慢性萎缩性胃炎临床研究.博士学位论文.广州中医药大学,2006.
[26]张伦.萎胃汤治疗慢性萎缩性胃炎的临床观察与实验研究.博士学位论文.广州中医药大学,2010.
[27]郑宏冰.胃宁颗粒治疗慢性萎缩性胃炎脾胃湿热证的临床与实验研究.硕士学位论文.山东中医药大学,2004.
[28]何善明,袁海锋.健脾化瘀解毒法治疗慢性萎缩性胃炎不典型增生的临床研究.新中医,2008,40(2)：35-36.
[29]俞芹,黄海芹,曹力.化浊解毒清幽方加减治疗幽门螺杆菌相关性胃炎临床观察.广州中医药大学学报,2012,29(2)：139-141
[30]Tran Thi Nga. Danh gia hieu qua dieu tri viem da day man tinh bang tra tan BVT gia giam. Luan van Thac si,2005.
[31]欧文娥,朱秀,杨晓恒,等.化瘀通络养阴和胃法治疗慢性萎缩性胃炎86例总结.湖南中医杂志,2008,24(2)：25-27.
[32]郭涛.幽门螺杆菌及其相关细胞因子对胃上皮细胞增殖／凋亡和离体壁细胞酸分泌的调节及机制初探.博士学位论文.中国协和医科大学,2004.
[33]朱立鸣,段永强,成映霞,等.治萎防变胶囊对慢性萎缩性胃炎大鼠血清胃泌素和胃酸含量的影响.中国中医基础医学杂志,2009,(15)11：834-835.
[34]段永强,李兰珍,成映霞,等.胃炎灵胶囊对慢性萎缩性胃炎模型大鼠胃腺分泌功能影响的研究.时珍国医国药,2007,(18)10：2404-2405.
[35]李佃贵,杜艳茹,郭敏,等.化浊解毒方对慢性萎缩性胃炎胃癌前病变患者胃液成分及肿瘤标记物的影响.中国中西医结合杂志,2011,(31)4：496-499.
[36]席银雪,宋鑫,陈惠新,等.微血管密度在胃癌癌变多阶段组织中的表达及其意义.中华医学杂志,2006,86(48)：3405-3407.
[37]席银雪,彭挺生.免疫组化法染色在不同病变胃粘膜、组织中价值研究.遵义医学院学,2010,(33)6：550-552.
[38]闻淑军,张志广.Hp感染与胃癌组织中MVD及VEGF表达的相关性研究.天津医药,2008,36(2)：99-102.
[39]何文波,高国林,候妹等.大鼠慢性萎缩性胃炎时粘膜血管病变与胃癌的关系.世界华人消化杂志,1999；7(2)：130-131.
[40]邢燕玲,游俊.四君子汤对脾气虚型慢性萎缩性胃炎大鼠胃粘膜血流量及血清SOD与MDA含量的影响.实验中医药学,2007,(8)23：22-24.
[41]陶厚权,邹寿椿,王瑞年,等.血管生成与胃癌发生之间关系的实验研究.世界华人消化杂志,2003,11(1)：43-46.
[42]孟捷.慢性萎缩性胃炎证候规律探讨和消痞颗粒治疗慢性萎缩性胃炎癌前病变的机理研究.博士学位论文.北京中医药大学,2005.
[43]高绍芳.化浊解毒法对慢性萎缩性胃炎癌前病变相关基因和血管生成机制影响的研究.博士学位论文.北京中医药大学,2010.
[44]李兰珍,朱向东,段永强,等.胃炎灵胶囊对慢性萎缩性胃炎模型大鼠血清SOD活性和MDA含量及胃粘膜组织形态的影响.中医药学报,2007,35(4)：23-25.
[45]魏国娈,刘新生,邵祖燕,等.五丹胃福汤对慢性萎缩性胃炎模型大鼠自由基水平的影响.中国中西医结合消化杂志,2002,10(6)：352-354.
[46]阮氏秋河.胃炎一号对慢性萎缩性胃炎癌前病变的干预作用.博士学位论文.广州中医药大学,2009.
[47]王春生,刘亚军,周晶.开痞合剂对实验性慢性萎缩性胃炎大鼠NO、MDA、SOD的影响.北京中医,2005,(24)4：249-250.
[48]吴晋兰,陈展,朱飞叶,等.乐胃饮对慢性萎缩性胃炎大鼠血清氧自由基及胃粘膜组织形态的影响.中华中医药学刊,2012,(30)2：340-341.
[49]邢燕玲,游俊.四君子汤对脾气虚型慢性萎缩性胃炎大鼠胃粘膜血流量及血清SOD与MDA含量的影响.实验中医药学,2007,(8)23.
[50]李勇.胃痞舒分散片的研制及治疗CAG癌前病变机理的初步研究.硕士学位论文.山东中医药大学,2004.
[51]曹志群.芪莲舒痞颗粒对CAG癌前病变临床及抑制血管生成因子的研究.博士学位论文.山东中医药大学,2002.
[52]谢慧臣.胃炎冲剂对慢性萎缩性胃炎大鼠胃粘膜的保护作用.湖北民族学院学报医学版,2005,(22)1：19-21.
[53]杜铁良,陈玉兴,赵自明,等.愈萎平颗粒对慢性萎缩性胃炎模型大鼠胃粘膜的保护作用.江西中医学院学报,2011,(23)5：66-68.
[54]舒劲,李喜香,任远,等.制萎扶胃浓缩丸对慢性萎缩性胃炎模型大鼠SOD活性、MDA和NO含量影响.中国实验方剂学杂志,2011,17(2)：160-162.
[55]田汉文,刘小康,肖逸,等.猴头菌提取物颗粒对大鼠慢性萎缩性胃炎的预防作用.中国医院药学杂志,2009,(29)20：1764-1767.
[56]潘华峰,赵霞,刘静.健脾化瘀解毒法在萎缩性胃炎防治中的作用.中药新药与临床药 理,2005,16(3)：229-231.
[57]王萍.慢性萎缩性胃炎中医证治规律探讨及临床疗效评价研究.博士学位论文.中国中医科学院,2008.
[58]高学敏.中药学.中国中医药出版社,2010：137-138,321-322,427-430.
[59]秦汝兰.太子参多糖的提取及抗疲劳作用的研究.人参研究,2010；3.18.
[60]蔡晶,李孝栋,陈旭征,等.太子参多糖粗提物对小鼠免疫功能的影响.福建中医学院学报,2005,03.
[61]曾锦章,张万岱,张真书,等.慢性胃炎中医辨证与血浆中胃泌素及生长抑素变化的研究.中国中西医结合脾胃杂志,1998,6(2)：73-75.
[62]Han J, Lee J-D, Bills L, et al. A MAPkinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science,1994,265:808-811.
[63]孙弼刚,沈鹰,刘正民.不同程度脾虚胃院痛患者胃粘膜防御功能变化.广州中医药大学学报,1998,15(3)：188-190.
[64]王秀琴.实验性脾虚症与胃肠内分泌细胞的研究.北京实验动物科学管理,2004,11(3)：56-58.
[65]袁媛.黄芪多糖对内毒素致小肠上皮细胞损伤的保护作用.博士学位论文.中国医科大学,2008.
[66]路景涛,陈敏株.复方黄芪提取物对细菌脂多糖诱导大鼠腹腔巨噬细胞分泌TNF、NO及IL-1的影响.安徽医药,2006,10(5)：330-331.
[67]高岩.健脾活血法治疗慢性萎缩性胃炎45例.陕西中医,2010,31(10)：1357-1359.
[68]庄步辉.健脾化痰方治疗慢性萎缩性胃炎临床观察.中医中药,2011,18(2)：93-94.
[69]马文军.健脾活血清热法治疗慢性萎缩性胃炎60例.陕西中医学院学报,2011,34(2)： 45-46.
[70]丁建华.健脾利湿化瘀法治疗慢性萎缩性胃炎临床观察.辽宁中医药大学学报,2013,15(1)：183-184.
[71]谢晶日,张皓婷,梁国英.欣胃颗粒治疗胃癌前病变气阴两虚兼瘀型患者的临床观察.中国中西医结合消化杂志,2010(5)：288-290.
[72]王玲玲. “养胃抑萎汤”治疗慢性萎缩性胃炎癌前病变53例临床研究.江苏中医药,2012,44(8)：18-19.
[73]陈国忠,黄贵华,李桂贤,等.益气活血养阴颗粒治疗慢性萎缩性胃炎癌前病变的临床研究.广西医科大学学报,2010,27(4)：577-579.
[74]张颜伟,郭喜俊,赵见文,等.化浊解毒方治疗慢性萎缩性胃炎癌前病变的临床研究.世界中西医结合杂志,2011,6(1)：36-38.
[75]李佃贵,杜艳茹,郭敏,等.化浊解毒治疗胃癌前病变临床疗效及对微量元素的影响.中药材,2011,34(1)：158-160.
[76]霍永利,李佃贵,马小顺.化浊解毒法治疗胃癌前病变患者61例.中医杂志,2011,52(8)：698-699.
[77]潘华峰,赵霞,鞠晓云,等.胃痞消对实验性大鼠慢性萎缩性胃炎的作用.中国中西医结合消化杂志,2005,(13)5：287-288.
[78]赵霞,潘华峰,鞠晓云,等.胃痞消抑制慢性萎缩性胃炎脾虚大鼠胃粘膜上皮细胞凋亡及调控蛋白Caspase-3和P53表达.中国新药杂志,2007,16(13)：1018-1021.
[79]赵霞,潘华峰,鞠晓云,等.胃痞消对CAG脾虚大鼠胃粘膜上皮细胞凋亡及调控蛋白Caspase-3影响的研究.中国中医基础医学杂志,2007,13(1)：42-43.
[80]郑筱萸.中药新药临床研究指导原则(试行).中国医药科技出版社,2002：124-129.
[81]Monleon E, MonzonM, Hortells P, et al. Detection f PrPsc on lyphoid tissues from naturally affected scrapie aninals comparison of three visulization systems J Histichem,2004 Feb,52 (2):145-51.
[82]梁晓俐.病理学基础与实验技术.北京：军事医学科学出版社,2004：204-205.
[83]赵自明,曾晓会,黄雪君,等.愈萎平对脾虚型慢性萎缩性胃炎模型大鼠胃病理的影响.中国现代药物应用,2009,3(15)：114-115.
[84]任宏义.慢性萎缩性肖炎脾虚证的病理组织学与超微结构观察.中国中西医结合杂志,1992：12(10)：593.
[85]邓伟民,刘友章.中医脾本质的现代研究.人民军医出版社,2010
[86]徐景藩.脾胃病临论经验集粹.科学出版社,2010.
[87]李杰.从血管新生角度探讨健脾法与活血法对胃癌前病变转归的影响作用研究.硕士学位论文.第四军医大学,2010.
[88]蔡淦.治疗慢性萎缩性胃炎及其癌前病变的经验.江苏中医药,2007,39(8)：1
[89]何晓晖,陈文,陈建章,等.双蒲散治疗大鼠慢性萎缩性胃炎的实验研究.上海中医药杂志,2008,(42)3：66-68.
[90]祁宏,耿曙光,许定仁,等.萎胃康治疗慢性萎缩性胃炎的疗效及血液流变学的影响.中国中西医结合急救杂志,2004；11(1)：42-44.
[91]许宏俐,顾洛,田苏平,等.侧脑室内注射降钙素基因相关肽对大鼠胃粘膜血流量的影响.江苏临床医学杂志,2001,5(5)：375.
[92]君国有,朱磊.慢性胃炎辨证与成方治疗.科学技术文献出版社,2006.
[93]高明奇,林庚.丹参提取物F对乙醇诱导的大鼠胃粘膜损伤和胃粘膜微血管损伤的抑制作用及对脂质过氧化物的影响.世界科学技术-中医药现代化,2008,10(3)：118-122.郑铁生,鄢盛恺.临床生物化学检验诊断.中国医药科技出版社,2004：371-386.
[94]赵立宇,褚惠民,李福凤,等.慢性胃炎患者SOD、MDA检测与中医证型的相关性初探.中
[95]华现代中西医杂志,2004,2(12)：63-65.
[2]Melanie Nicole Weck and Hermann Brenner. Prevalence of chronic atrophic gastritis in different parts of the world. Cancer Epidemiol Biomarkers,2006, Prev 15 (6):1083-94.
[3]戴德哉.临床医学概论.科学出版社,2011：124-126.
[4]柴可夫.慢性胃炎.科学技术文献出版社,2000：1-4.
[5]孟静岩.慢性萎缩性胃炎.中国医药科技出版社,2003：28-33.
[6]张经济,连至诚,许冠荪,等.消化道生理及病理生理学.广东科技出版社,1997：448-479.
[7]陆为民,刘万里,吴静,徐陆周,等.慢性萎缩性胃炎中医特色疗法.人民军医出版社,2012.
[8]刘友章.中西医结合内科学.广东高等教育出版社,2007：333-339.
[9]陆为民,万力生.中医内科临证治要.学苑出版社,2012：120-132.
[10]朱文锋,何清湖.现代中医临床诊断学.人民卫生出版社,2003：403-411,549-550.
[11]张杰,章天寿.从“虚”“毒”“瘀”论治慢性萎缩性胃炎.中国中医基础医学杂志,2005,11(1)：44-45.
[12]张道友.现代临床检验正常值手册.安徽科学技术出版社,2001：101-108.
[13]孙自镛.实验诊断临床指南.第二版.科学出版社,2004：187-191.
[14]魏玉霞.慢性萎缩性胃炎近10年中医文献研究.博士学位论文.北京中医药大学,2012.
[15]Stater IF. Freeracdicalsand tissue injury:Fact and ficttion Brj Cancer.1987, ss (Sujpp. Ⅷ):5.
[16]金武丕.慢性萎缩性胃炎病人胃粘膜MDA和SOD测定及其意义.中国基层医药,1999,(6)5：271-272.
[17]魏玥.益气化瘀解毒法对慢性萎缩性胃炎伴异型增生大鼠干预的实验研究.博士学位论文.北京中医药大学,2012.
[18]孙晓明,孟凡明,李丽晴,等.健脾活血.方治疗慢性萎缩性胃炎伴肠化增生55例.陕西中医,2011,32(1)：11-12.
[19]张风岭. 自拟扶正活血汤治疗慢性萎缩性胃炎58例观察.中医药临床杂志,2005,17(5)：479-480.
[20]赖逸贵.胃炎Ⅰ号对大鼠慢性萎缩性胃炎胃粘膜细胞外基质成份调控机制研究.博士学位论文.广州中医药大学,2009.
[21]苏和.牛兴东学术思想及治疗慢性萎缩性胃炎经验总结.硕士学位论文.北京中医药大 学,2012.
[22]张秀娟.中药通过线粒体途径治疗胃癌前病变大鼠的实验研究.博士学位论文.辽宁中医药大学,2010.
[23]许颖,陈菲.益胃煎加减治疗慢性萎缩性胃炎气虚血瘀型30例.陕西中医,2010,(31)9：1130-1131.
[24]马然.慢性萎缩性胃炎中医症候学研究.中医学专业七年制学位论文.北京中医药大学,2005.
[25]延卫东.萎胃复元汤治疗慢性萎缩性胃炎临床研究.博士学位论文.广州中医药大学,2006.
[26]张伦.萎胃汤治疗慢性萎缩性胃炎的临床观察与实验研究.博士学位论文.广州中医药大学,2010.
[27]郑宏冰.胃宁颗粒治疗慢性萎缩性胃炎脾胃湿热证的临床与实验研究.硕士学位论文.山东中医药大学,2004.
[28]何善明,袁海锋.健脾化瘀解毒法治疗慢性萎缩性胃炎不典型增生的临床研究.新中医,2008,40(2)：35-36.
[29]俞芹,黄海芹,曹力.化浊解毒清幽方加减治疗幽门螺杆菌相关性胃炎临床观察.广州中医药大学学报,2012,29(2)：139-141
[30]Tran Thi Nga. Danh gia hieu qua dieu tri viem da day man tinh bang tra tan BVT gia giam. Luan van Thac si,2005.
[31]欧文娥,朱秀,杨晓恒,等.化瘀通络养阴和胃法治疗慢性萎缩性胃炎86例总结.湖南中医杂志,2008,24(2)：25-27.
[32]郭涛.幽门螺杆菌及其相关细胞因子对胃上皮细胞增殖／凋亡和离体壁细胞酸分泌的调节及机制初探.博士学位论文.中国协和医科大学,2004.
[33]朱立鸣,段永强,成映霞,等.治萎防变胶囊对慢性萎缩性胃炎大鼠血清胃泌素和胃酸含量的影响.中国中医基础医学杂志,2009,(15)11：834-835.
[34]段永强,李兰珍,成映霞,等.胃炎灵胶囊对慢性萎缩性胃炎模型大鼠胃腺分泌功能影响的研究.时珍国医国药,2007,(18)10：2404-2405.
[35]李佃贵,杜艳茹,郭敏,等.化浊解毒方对慢性萎缩性胃炎胃癌前病变患者胃液成分及肿瘤标记物的影响.中国中西医结合杂志,2011,(31)4：496-499.
[36]席银雪,宋鑫,陈惠新,等.微血管密度在胃癌癌变多阶段组织中的表达及其意义.中华医学杂志,2006,86(48)：3405-3407.
[37]席银雪,彭挺生.免疫组化法染色在不同病变胃粘膜、组织中价值研究.遵义医学院学,2010,(33)6：550-552.
[38]闻淑军,张志广.Hp感染与胃癌组织中MVD及VEGF表达的相关性研究.天津医药,2008,36(2)：99-102.
[39]何文波,高国林,候妹等.大鼠慢性萎缩性胃炎时粘膜血管病变与胃癌的关系.世界华人消化杂志,1999；7(2)：130-131.
[40]邢燕玲,游俊.四君子汤对脾气虚型慢性萎缩性胃炎大鼠胃粘膜血流量及血清SOD与MDA含量的影响.实验中医药学,2007,(8)23：22-24.
[41]陶厚权,邹寿椿,王瑞年,等.血管生成与胃癌发生之间关系的实验研究.世界华人消化杂志,2003,11(1)：43-46.
[42]孟捷.慢性萎缩性胃炎证候规律探讨和消痞颗粒治疗慢性萎缩性胃炎癌前病变的机理研究.博士学位论文.北京中医药大学,2005.
[43]高绍芳.化浊解毒法对慢性萎缩性胃炎癌前病变相关基因和血管生成机制影响的研究.博士学位论文.北京中医药大学,2010.
[44]李兰珍,朱向东,段永强,等.胃炎灵胶囊对慢性萎缩性胃炎模型大鼠血清SOD活性和MDA含量及胃粘膜组织形态的影响.中医药学报,2007,35(4)：23-25.
[45]魏国娈,刘新生,邵祖燕,等.五丹胃福汤对慢性萎缩性胃炎模型大鼠自由基水平的影响.中国中西医结合消化杂志,2002,10(6)：352-354.
[46]阮氏秋河.胃炎一号对慢性萎缩性胃炎癌前病变的干预作用.博士学位论文.广州中医药大学,2009.
[47]王春生,刘亚军,周晶.开痞合剂对实验性慢性萎缩性胃炎大鼠NO、MDA、SOD的影响.北京中医,2005,(24)4：249-250.
[48]吴晋兰,陈展,朱飞叶,等.乐胃饮对慢性萎缩性胃炎大鼠血清氧自由基及胃粘膜组织形态的影响.中华中医药学刊,2012,(30)2：340-341.
[49]邢燕玲,游俊.四君子汤对脾气虚型慢性萎缩性胃炎大鼠胃粘膜血流量及血清SOD与MDA含量的影响.实验中医药学,2007,(8)23.
[50]李勇.胃痞舒分散片的研制及治疗CAG癌前病变机理的初步研究.硕士学位论文.山东中医药大学,2004.
[51]曹志群.芪莲舒痞颗粒对CAG癌前病变临床及抑制血管生成因子的研究.博士学位论文.山东中医药大学,2002.
[52]谢慧臣.胃炎冲剂对慢性萎缩性胃炎大鼠胃粘膜的保护作用.湖北民族学院学报医学版,2005,(22)1：19-21.
[53]杜铁良,陈玉兴,赵自明,等.愈萎平颗粒对慢性萎缩性胃炎模型大鼠胃粘膜的保护作用.江西中医学院学报,2011,(23)5：66-68.
[54]舒劲,李喜香,任远,等.制萎扶胃浓缩丸对慢性萎缩性胃炎模型大鼠SOD活性、MDA和NO含量影响.中国实验方剂学杂志,2011,17(2)：160-162.
[55]田汉文,刘小康,肖逸,等.猴头菌提取物颗粒对大鼠慢性萎缩性胃炎的预防作用.中国医院药学杂志,2009,(29)20：1764-1767.
[56]潘华峰,赵霞,刘静.健脾化瘀解毒法在萎缩性胃炎防治中的作用.中药新药与临床药 理,2005,16(3)：229-231.
[57]王萍.慢性萎缩性胃炎中医证治规律探讨及临床疗效评价研究.博士学位论文.中国中医科学院,2008.
[58]高学敏.中药学.中国中医药出版社,2010：137-138,321-322,427-430.
[59]秦汝兰.太子参多糖的提取及抗疲劳作用的研究.人参研究,2010；3.18.
[60]蔡晶,李孝栋,陈旭征,等.太子参多糖粗提物对小鼠免疫功能的影响.福建中医学院学报,2005,03.
[61]曾锦章,张万岱,张真书,等.慢性胃炎中医辨证与血浆中胃泌素及生长抑素变化的研究.中国中西医结合脾胃杂志,1998,6(2)：73-75.
[62]Han J, Lee J-D, Bills L, et al. A MAPkinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science,1994,265:808-811.
[63]孙弼刚,沈鹰,刘正民.不同程度脾虚胃院痛患者胃粘膜防御功能变化.广州中医药大学学报,1998,15(3)：188-190.
[64]王秀琴.实验性脾虚症与胃肠内分泌细胞的研究.北京实验动物科学管理,2004,11(3)：56-58.
[65]袁媛.黄芪多糖对内毒素致小肠上皮细胞损伤的保护作用.博士学位论文.中国医科大学,2008.
[66]路景涛,陈敏株.复方黄芪提取物对细菌脂多糖诱导大鼠腹腔巨噬细胞分泌TNF、NO及IL-1的影响.安徽医药,2006,10(5)：330-331.
[67]高岩.健脾活血法治疗慢性萎缩性胃炎45例.陕西中医,2010,31(10)：1357-1359.
[68]庄步辉.健脾化痰方治疗慢性萎缩性胃炎临床观察.中医中药,2011,18(2)：93-94.
[69]马文军.健脾活血清热法治疗慢性萎缩性胃炎60例.陕西中医学院学报,2011,34(2)： 45-46.
[70]丁建华.健脾利湿化瘀法治疗慢性萎缩性胃炎临床观察.辽宁中医药大学学报,2013,15(1)：183-184.
[71]谢晶日,张皓婷,梁国英.欣胃颗粒治疗胃癌前病变气阴两虚兼瘀型患者的临床观察.中国中西医结合消化杂志,2010(5)：288-290.
[72]王玲玲. “养胃抑萎汤”治疗慢性萎缩性胃炎癌前病变53例临床研究.江苏中医药,2012,44(8)：18-19.
[73]陈国忠,黄贵华,李桂贤,等.益气活血养阴颗粒治疗慢性萎缩性胃炎癌前病变的临床研究.广西医科大学学报,2010,27(4)：577-579.
[74]张颜伟,郭喜俊,赵见文,等.化浊解毒方治疗慢性萎缩性胃炎癌前病变的临床研究.世界中西医结合杂志,2011,6(1)：36-38.
[75]李佃贵,杜艳茹,郭敏,等.化浊解毒治疗胃癌前病变临床疗效及对微量元素的影响.中药材,2011,34(1)：158-160.
[76]霍永利,李佃贵,马小顺.化浊解毒法治疗胃癌前病变患者61例.中医杂志,2011,52(8)：698-699.
[77]潘华峰,赵霞,鞠晓云,等.胃痞消对实验性大鼠慢性萎缩性胃炎的作用.中国中西医结合消化杂志,2005,(13)5：287-288.
[78]赵霞,潘华峰,鞠晓云,等.胃痞消抑制慢性萎缩性胃炎脾虚大鼠胃粘膜上皮细胞凋亡及调控蛋白Caspase-3和P53表达.中国新药杂志,2007,16(13)：1018-1021.
[79]赵霞,潘华峰,鞠晓云,等.胃痞消对CAG脾虚大鼠胃粘膜上皮细胞凋亡及调控蛋白Caspase-3影响的研究.中国中医基础医学杂志,2007,13(1)：42-43.
[80]郑筱萸.中药新药临床研究指导原则(试行).中国医药科技出版社,2002：124-129.
[81]Monleon E, MonzonM, Hortells P, et al. Detection f PrPsc on lyphoid tissues from naturally affected scrapie aninals comparison of three visulization systems J Histichem,2004 Feb,52 (2):145-51.
[82]梁晓俐.病理学基础与实验技术.北京：军事医学科学出版社,2004：204-205.
[83]赵自明,曾晓会,黄雪君,等.愈萎平对脾虚型慢性萎缩性胃炎模型大鼠胃病理的影响.中国现代药物应用,2009,3(15)：114-115.
[84]任宏义.慢性萎缩性肖炎脾虚证的病理组织学与超微结构观察.中国中西医结合杂志,1992：12(10)：593.
[85]邓伟民,刘友章.中医脾本质的现代研究.人民军医出版社,2010
[86]徐景藩.脾胃病临论经验集粹.科学出版社,2010.
[87]李杰.从血管新生角度探讨健脾法与活血法对胃癌前病变转归的影响作用研究.硕士学位论文.第四军医大学,2010.
[88]蔡淦.治疗慢性萎缩性胃炎及其癌前病变的经验.江苏中医药,2007,39(8)：1
[89]何晓晖,陈文,陈建章,等.双蒲散治疗大鼠慢性萎缩性胃炎的实验研究.上海中医药杂志,2008,(42)3：66-68.
[90]祁宏,耿曙光,许定仁,等.萎胃康治疗慢性萎缩性胃炎的疗效及血液流变学的影响.中国中西医结合急救杂志,2004；11(1)：42-44.
[91]许宏俐,顾洛,田苏平,等.侧脑室内注射降钙素基因相关肽对大鼠胃粘膜血流量的影响.江苏临床医学杂志,2001,5(5)：375.
[92]君国有,朱磊.慢性胃炎辨证与成方治疗.科学技术文献出版社,2006.
[93]高明奇,林庚.丹参提取物F对乙醇诱导的大鼠胃粘膜损伤和胃粘膜微血管损伤的抑制作用及对脂质过氧化物的影响.世界科学技术-中医药现代化,2008,10(3)：118-122.郑铁生,鄢盛恺.临床生物化学检验诊断.中国医药科技出版社,2004：371-386.
[94]赵立宇,褚惠民,李福凤,等.慢性胃炎患者SOD、MDA检测与中医证型的相关性初探.中
[95]华现代中西医杂志,2004,2(12)：63-65.